ALPMF (Astellas Pharma) Other Long-Term Liabilities : $1,166 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Other Long-Term Liabilities?

Astellas Pharma's other long-term liabilities for the quarter that ended in Mar. 2025 was $1,166 Mil.

Astellas Pharma's quarterly other long-term liabilities declined from Sep. 2024 ($1,296 Mil) to Dec. 2024 ($1,204 Mil) and declined from Dec. 2024 ($1,204 Mil) to Mar. 2025 ($1,166 Mil).

Astellas Pharma's annual other long-term liabilities increased from Mar. 2023 ($1,074 Mil) to Mar. 2024 ($1,424 Mil) but then declined from Mar. 2024 ($1,424 Mil) to Mar. 2025 ($1,166 Mil).

Astellas Pharma Other Long-Term Liabilities Historical Data

The historical data trend for Astellas Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Other Long-Term Liabilities Chart

Astellas Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Other Long-Term Liabilities

Get a 7-Day Free Trial

2,352.91

1,237.79

1,073.55

1,423.58

1,166.06

Astellas Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															1,423.58	1,318.48	1,295.96	1,204.48	1,166.06

Astellas Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Astellas Pharma Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.